Company
Laigo Bio
- Biotech
- Headquarters:
- Utrecht, The Netherlands
- Offices:
- Utrecht, Netherlands
Description
Laigo Bio develops SureTACs, bispecific molecules that bind membrane targets and membrane E3 ligases to drive ubiquitin-mediated, lysosomal degradation of cell-surface proteins for therapeutic applications such as oncology and immunology.
Laigo Bio is located in the Netherlands ecosystem.
Related
BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
Arctic BioscienceArctic Bioscience develops and manufactures marine membrane lipid extracts for pharmaceutical and nutraceutical applications, including…
CellfionCellfion develops and manufactures PFAS-free, cellulose-based membranes using functionalized nanocellulose, with adjustable surface…
ZoBioZoBio helps biopharma companies identify small molecules for drug targets, applying protein-science expertise, biophysical and biochemical…
Captor TherapeuticsCaptor Therapeutics develops therapeutics using targeted protein degradation (TPD) to address high‑unmet‑need diseases such as cancer and…
NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…
Numab TherapeuticsNumab Therapeutics engineers multispecific antibodies, combining antibody engineering and Swiss scientific expertise to build a proprietary…
Molecular PartnersMolecular Partners develops DARPin therapeutics, including Radio-DARPins and logic-gated Switch-DARPins, to target DLL3, FAP x CD40, and…